---
title: "MicroPort MedBot’s Toumai Surgical Robot Tops 200 Global Installations"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290990958.md"
description: "Shanghai MicroPort MedBot announced its Toumai surgical robot has surpassed 200 global commercial installations and secured over 300 orders. The system ranks first among domestic brands and top two globally for new installations this year, with deployments in over 60 countries. It holds a leading position in China and is gaining traction in Europe, being the only EU-approved robot for remote surgery. Analysts maintain a 'Buy' rating with a HK$45 price target."
datetime: "2026-06-26T15:21:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290990958.md)
  - [en](https://longbridge.com/en/news/290990958.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290990958.md)
generator: "portal-rs"
---

# MicroPort MedBot’s Toumai Surgical Robot Tops 200 Global Installations

Shanghai MicroPort MedBot (Group) Co., Ltd. Class H ( (HK:2252) ) has issued an announcement.

Shanghai MicroPort MedBot said its flagship Toumai Laparoscopic Surgical Robot has surpassed 200 commercial installations worldwide, following more than 300 global orders, with all deployed systems accepted by end customers. The system now ranks first among domestic brands and in the top two globally for new installations this year, underscoring rapid maturation of its clinical ecosystem and remote collaboration network.

Toumai has been installed in more than 60 countries and regions and is gaining traction in Europe, where it is the only surgical robot approved for remote surgery in the EU and is seeing strong uptake in markets such as Spain, Belgium, and the U.K. The robot has also secured a leading position in China by penetrating top-tier hospitals, while the group builds out a global training and support infrastructure to accelerate the commercial adoption of robotic and remote surgery, though investors are cautioned that the disclosed figures are preliminary and unaudited.

The most recent analyst rating on (HK:2252) stock is a Buy  
 with a HK$45.00 price target.  
 To see the full list of analyst forecasts on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H stock,  
 see the HK:2252 Stock Forecast page. 

**More about Shanghai MicroPort MedBot (Group) Co., Ltd. Class H**

Shanghai MicroPort MedBot (Group) Co., Ltd. is a mainland China-based medical technology company specializing in robotic-assisted surgical systems. Its core product, the Toumai Laparoscopic Surgical Robot, targets both domestic and international hospital markets, with a focus on advancing remote surgery capabilities and building a global clinical and training ecosystem.

**Average Trading Volume:** 5,964,298

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$23.19B

### Related Stocks

- [02252.HK](https://longbridge.com/en/quote/02252.HK.md)

## Related News & Research

- [MicroPort MedBot Forecasts First Semi-Annual Profit on Surging Robot Sales](https://longbridge.com/en/news/293489688.md)
- [MicroPort MedBot delays 2026 interim results, trading suspended amid lease review](https://longbridge.com/en/news/297580474.md)
- [An NEA partner says not every AI task needs frontier intelligence](https://longbridge.com/en/news/298434703.md)
- [AI agents keep finding ways to bend the rules. Here are some of the wildest.](https://longbridge.com/en/news/298138114.md)
- [Exclusive-After outrunning Bolt, China's robot champion races towards real-world work](https://longbridge.com/en/news/298516320.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**